Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Key events next week - healthcare

Published 01/26/2018, 08:01 AM
© Reuters. Key events next week - healthcare
  • Healthcare investors have a full slate of events ahead next week:
  • Sunday (1/28)(three days): Association of Cancer Executives Annual Meeting, Portland, OR.
  • FDA action date for Roche's (OTCQX:RHHBY) Perjeta for HER2+ breast cancer (decision should be announced by Friday, 1/26).
  • Monday (1/29)(two days): NobelCon14, Ft. Lauderdale, FL. Presenters (1/29): BioTime (NYSEMKT:BTX), Anavex Life Sciences (NASDAQ:AVXL), Tonix Pharmaceuticals (NASDAQ:TNXP), Interpace Diagnostics (NASDAQ:IDXG), MannKind (NASDAQ:MNKD), ESSA Pharma (NASDAQ:EPIX).
  • Presenters (1/30): Spectrum Pharmaceuticals (NASDAQ:SPPI), Dicerna Pharmaceuticals (NASDAQ:DRNA), Cyclacel Pharmaceuticals (NASDAQ:CYCC), Provant Health (OTCQX:HPHW), Humanigen (OTCQB:HGEN), ContraVir Pharmaceuticals (NASDAQ:CTRV)(may be Monday).
  • Zealand Pharma A/S (OTCPK:ZLDPF) business update.
  • Tuesday (1/30): Stryker (NYSE:SYK) Q4 results (premarket), Illumina (NASDAQ:ILMN) Q4 results (after the close).
  • Wednesday (1/31)(three days): Cholangiocarcinoma Foundation Annual Conference, Salt Lake City, UT. Zymeworks (NYSE:ZYME) presenting corporate overview.
  • Q4 results (premarket): Eli Lilly (NYSE:LLY), Baxter International (NYSE:BAX).
  • Thursday (2/1): 10th Annual T-cell Lymphoma Forum, La Jolla, CA (three days). Miragen Therapeutics (NASDAQ:MGEN): Phase 1 data on MRG-106 (2/2).
  • 3rd Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), San Diego, CA. TG Therapeutics (NASDAQ:TGTX): Phase 2a data on ublituximab in relapsing MS.
  • Advances Against Aspergillosis conference, Lisbon, Portugal. Pulmatrix (NASDAQ:PULM): preclinical data on pulmazole.
  • Q4 earnings: premarket: Quest Diagnostics (NYSE:DGX), Boston Scientific (NYSE:BSX). After the close: Edwards Lifesciences (NYSE:EW).
  • Friday (2/2): FDA action date for AMAG Pharmaceuticals' Feraheme for all adult IDA patients.
  • FDA action date for Portola Pharmaceuticals' (NASDAQ:PTLA) AndexXa resubmitted BLA (extended to May 4).
  • Saturday (2/3): FDA action date for Amgen's (NASDAQ:AMGN) XGEVA to include multiple myeloma patients. A decision should be announced no later than Friday.
  • Now read: Your Daily Pharma Scoop: Portola Still Attractive, Johnson & Johnson (NYSE:JNJ) Reports Q4 Results, Cerus Reports Positive Results
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.